Literature DB >> 35880639

ERK1/2-RSK2 Signaling in Regulation of ERα-Mediated Responses.

Deborah A Lannigan1,2.   

Abstract

Signaling via extracellular regulated kinase 1/2 (ERK1/2) and p90 ribosomal S6 kinase (RSK), a downstream effector, mediates numerous processes. For example, ERK1/2-RSK signaling is essential for estrogen homeostasis in the mammary gland and uterus to maintain physiological responsiveness. This review will focus on the coordination of ERK1/2-RSK2 and estrogen signaling through estrogen receptor alpha (ERα). The interrelationship and the feedback mechanisms between these pathways occurs at the level of transcription, translation, and posttranslational modification. Identifying how ERK1/2-RSK2 and estrogen signaling cooperate in homeostasis and disease may lead to novel therapeutic approaches in estrogen-dependent disorders.
© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  ERK1/2; ERα; MAPK; RSK; estrogen; p90 RSK; p90 ribosomal S6 kinase

Mesh:

Substances:

Year:  2022        PMID: 35880639      PMCID: PMC9337271          DOI: 10.1210/endocr/bqac106

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   5.051


  106 in total

1.  Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation.

Authors:  Jeffrey A Smith; Celeste E Poteet-Smith; Yaming Xu; Timothy M Errington; Sidney M Hecht; Deborah A Lannigan
Journal:  Cancer Res       Date:  2005-02-01       Impact factor: 12.701

Review 2.  Estrogen Receptors: New Directions in the New Millennium.

Authors:  Sylvia C Hewitt; Kenneth S Korach
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

Review 3.  A compendium of ERK targets.

Authors:  Evrim B Ünal; Florian Uhlitz; Nils Blüthgen
Journal:  FEBS Lett       Date:  2017-07-25       Impact factor: 4.124

4.  Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice.

Authors:  G Pagès; S Guérin; D Grall; F Bonino; A Smith; F Anjuere; P Auberger; J Pouysségur
Journal:  Science       Date:  1999-11-12       Impact factor: 47.728

5.  Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer.

Authors:  Hiroko Yamashita; Satoru Takahashi; Yukashi Ito; Toshinari Yamashita; Yoshiaki Ando; Tatsuya Toyama; Hiroshi Sugiura; Nobuyasu Yoshimoto; Shunzo Kobayashi; Yoshitaka Fujii; Hirotaka Iwase
Journal:  Cancer Sci       Date:  2009-07-06       Impact factor: 6.716

6.  EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics.

Authors:  Daniel M Freed; Nicholas J Bessman; Anatoly Kiyatkin; Emanuel Salazar-Cavazos; Patrick O Byrne; Jason O Moore; Christopher C Valley; Kathryn M Ferguson; Daniel J Leahy; Diane S Lidke; Mark A Lemmon
Journal:  Cell       Date:  2017-10-05       Impact factor: 41.582

7.  ERα-Mediated Nuclear Sequestration of RSK2 Is Required for ER+ Breast Cancer Tumorigenesis.

Authors:  Katarzyna A Ludwik; Oliver G McDonald; David R Brenin; Deborah A Lannigan
Journal:  Cancer Res       Date:  2018-01-19       Impact factor: 12.701

8.  A molecular mechanism for the generation of ligand-dependent differential outputs by the epidermal growth factor receptor.

Authors:  Yongjian Huang; Jana Ognjenovic; Deepti Karandur; Kate Miller; Alan Merk; Sriram Subramaniam; John Kuriyan
Journal:  Elife       Date:  2021-11-30       Impact factor: 8.140

9.  N-terminal transactivation function, AF-1, of estrogen receptor alpha controls obesity through enhancement of energy expenditure.

Authors:  Yukitomo Arao; Katherine J Hamilton; Sydney L Lierz; Kenneth S Korach
Journal:  Mol Metab       Date:  2018-09-20       Impact factor: 7.422

Review 10.  Estrogen Receptor Beta (ERβ): A Ligand Activated Tumor Suppressor.

Authors:  Rahul Mal; Alexa Magner; Joel David; Jharna Datta; Meghna Vallabhaneni; Mahmoud Kassem; Jasmine Manouchehri; Natalie Willingham; Daniel Stover; Jeffery Vandeusen; Sagar Sardesai; Nicole Williams; Robert Wesolowski; Maryam Lustberg; Ramesh K Ganju; Bhuvaneswari Ramaswamy; Mathew A Cherian
Journal:  Front Oncol       Date:  2020-10-23       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.